Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.133,12
-0,09%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Deciphera Pharmaceuticals Inc (DCPH) Deciphera Pharmaceuticals Inc (DCPH) Notizie

DCPH

Deciphera Pharmaceuticals (DCPH)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DCPH
DataOraFonteTitoloSimboloCompagnia
14/06/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DCPHDeciphera Pharmaceuticals Inc
12/06/202402:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202423:18Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202423:02Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202423:01Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202415:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202415:18Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202415:15Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
03/06/202413:00Business WireDeciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The LancetNASDAQ:DCPHDeciphera Pharmaceuticals Inc
13/05/202412:32Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
13/05/202412:31Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
10/05/202413:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/05/202423:16Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/04/202413:00Business WireDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionNASDAQ:DCPHDeciphera Pharmaceuticals Inc
09/04/202413:00Business WireDeciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
27/02/202413:00Business WireDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
14/02/202422:06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202413:52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202413:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/02/202413:00Business WireDeciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202422:50Business WireDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024NASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202413:00Business WireDeciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
18/01/202417:13Business WireDeciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
08/01/202413:00Business WireDeciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product CompanyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
05/01/202413:00Business WireDeciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18NASDAQ:DCPHDeciphera Pharmaceuticals Inc
02/01/202413:00Business WireDeciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/12/202300:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/11/202313:00Business WireDeciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology SummitNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202312:01Business WireDeciphera Pharmaceuticals Announces Third Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202312:00Business WireDeciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCTNASDAQ:DCPHDeciphera Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DCPH

La tua Cronologia

LSE
ZX18
Citi Fun 24
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network